NCT06857734

Brief Summary

Vitamin C, also known as ascorbic acid, is a potent reducing agent and antioxidant that plays a crucial role in various metabolic processes.Vitamin B complex, a group of eight essential B vitamins, plays a crucial role in cellular metabolism, energy production, and maintaining nervous system health. There are few available studies on the effects of vitamin B injection on plasma inflammatory markers and its adjuvant analgesic effect along with the routine multimodal analgesia. Considering limited research and existing controversies in this field, the aim of present study is to evaluate the effects of preoperative and intraoperative vitamin B12 administration compared to vitamin C when used as a component of the multimodal analgesic technique in patients undergoing laparoscopic cholecystectomy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2025

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 27, 2025

Completed
2 days until next milestone

Study Start

First participant enrolled

March 1, 2025

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 4, 2025

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2026

Completed
Last Updated

March 4, 2025

Status Verified

February 1, 2025

Enrollment Period

1.2 years

First QC Date

February 27, 2025

Last Update Submit

February 27, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • The total dose of analgesics required postoperatively

    within the first 24 hours and the time to first request

Study Arms (3)

Group B

EXPERIMENTAL
Drug: Vitamin B Complex

Group C

EXPERIMENTAL
Drug: vitamin C

Group N

PLACEBO COMPARATOR
Drug: Placebo

Interventions

group of vit. B will recieve as an oral capsules for 4 days preoperative , and infusion of vitamin B complex 1ml diluted in 100 ml normal saline administered intravenously after anathesia induction .

Group B

group of vitamin C will recieve 1000 mg as an oral capsule for 4 days and infusion at dose of 50 mg/kg diluted in 100 ml normal saline administered iv after induction of anathesia .

Group C

patients will recieve placebo tablets with identical regimen preoperative and a placebo infusion of 100 ml normal saline after induction of anathesia ,prepared with identical appearance and taste by the pharmacist according to the randomization group.

Group N

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Adult patients (age 18-60 years)
  • American Society of Anesthesiologists (ASA) classification I-II
  • Patients undergoing laparoscopic cholecystectomy under general anaesthesia

You may not qualify if:

  • Hypersensitivity to vitamin B complex or vitamin C
  • History of chronic pain or use of opioids within the last month
  • Patient with inflammatory conditions
  • Severe renal or hepatic impairment
  • Patient with intellectual disabilities.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Benha university

Banhā, Egypt

Location

MeSH Terms

Conditions

Pain, Postoperative

Interventions

Vitamin B ComplexAscorbic Acid

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

VitaminsMicronutrientsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and UsesSugar AcidsAcids, AcyclicCarboxylic AcidsOrganic ChemicalsHydroxy AcidsCarbohydrates

Central Study Contacts

Islam M Hosainy, Master

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident

Study Record Dates

First Submitted

February 27, 2025

First Posted

March 4, 2025

Study Start

March 1, 2025

Primary Completion

May 1, 2026

Study Completion

May 1, 2026

Last Updated

March 4, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will share

Locations